Catalent, Inc. (NYSE:CTLT – Get Rating) has received a consensus rating of “Buy” from the nine research firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $142.88.
A number of research analysts have issued reports on CTLT shares. Morgan Stanley reduced their target price on shares of Catalent from $160.00 to $145.00 and set an “overweight” rating for the company in a research note on Wednesday, February 2nd. Barclays cut their price target on shares of Catalent from $160.00 to $130.00 and set an “overweight” rating on the stock in a report on Thursday, January 27th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Catalent from $129.00 to $110.00 and set a “hold” rating on the stock in a research report on Tuesday, April 12th. Finally, StockNews.com initiated coverage on shares of Catalent in a research report on Thursday, March 31st. They issued a “hold” rating for the company.
Shares of CTLT stock opened at $98.83 on Monday. Catalent has a 52 week low of $86.34 and a 52 week high of $142.64. The company has a market cap of $17.71 billion, a PE ratio of 35.81, a P/E/G ratio of 1.64 and a beta of 1.44. The company has a current ratio of 2.89, a quick ratio of 2.19 and a debt-to-equity ratio of 0.90. The company’s fifty day simple moving average is $101.47 and its 200-day simple moving average is $111.97.
A number of hedge funds have recently added to or reduced their stakes in CTLT. Prospera Financial Services Inc bought a new stake in shares of Catalent in the first quarter valued at about $33,000. Assetmark Inc. bought a new stake in shares of Catalent in the third quarter valued at about $34,000. Concord Wealth Partners boosted its position in shares of Catalent by 154.3% in the fourth quarter. Concord Wealth Partners now owns 267 shares of the company’s stock valued at $34,000 after acquiring an additional 162 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Catalent by 127.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 282 shares of the company’s stock valued at $36,000 after acquiring an additional 158 shares during the period. Finally, NEXT Financial Group Inc boosted its position in shares of Catalent by 69.8% in the fourth quarter. NEXT Financial Group Inc now owns 275 shares of the company’s stock valued at $36,000 after acquiring an additional 113 shares during the period. 98.05% of the stock is owned by hedge funds and other institutional investors.
Catalent Company Profile (Get Rating)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.